Cerebrolysin
Also known as: FPF-1070, Neuropeptide preparation, Porcine brain neuropeptides
Overview
Cerebrolysin is a lipid-free neuropeptide preparation produced by standardized enzymatic breakdown of purified porcine brain proteins. The resulting mixture of low-molecular-weight neuropeptides and free amino acids (all below 10 kDa) can cross the blood-brain barrier and interact directly with neurons, unlike most endogenous neurotrophic factors. With data from more than 200 clinical trials involving approximately 15,000 patients, it has one of the most extensive clinical databases of any nootropic peptide preparation, including studies in stroke, TBI, Alzheimer's disease, and vascular dementia.
Mechanism of Action
Cerebrolysin simultaneously activates multiple neuroprotective mechanisms: stimulating production of endogenous neurotrophic factors (BDNF, GDNF, NGF, CNTF) via direct peptide supply and upregulation of their synthesis; reducing excitotoxicity by modulating excessive glutamate activity; inhibiting apoptosis and reducing neurofibrillary tangle formation; promoting neurogenesis and synaptogenesis in the hippocampus; modifying NTF and Sonic Hedgehog signaling pathways governing myelination and neurovascular integrity; and activating CREB/PGC-1-alpha to suppress neuroinflammatory cytokines.
Potential Benefits
- Most extensively studied nootropic peptide preparation with >200 clinical trials
- Improved post-stroke functional independence (CARS trial)
- Reduced infarct volume and brain edema in TBI models
- Cognitive improvements in Alzheimer's disease (multiple RCTs with ADAS-cog improvements)
- Motor function improvements in stroke rehabilitation
- Supports neurogenesis and synaptic density in hippocampus
- Direct neurotrophic factor activity bypassing blood-brain barrier limitations
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 5-30 ml/day IV (clinical); 5-10 ml/day IM (research) |
| Beginner | 5 ml/day IM for 10 days |
| Intermediate | 10 ml/day IM or IV for 10-20 days |
| Advanced | 20-30 ml/day IV for 20-28 days (clinical stroke protocol) |
| Cycle Duration | 10-28 day courses |
| Cycle Off | 4-8 weeks between courses |
Cerebrolysin is a neuropeptide complex (not a single peptide) containing multiple neurotrophic peptide fragments. Clinical trials used 10-30 ml/day IV. IM dosing at 5-10 ml is practical for outpatient research protocols. Courses of 10-28 days are standard, followed by rest periods.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High — systemic distribution
Most common administration route for research peptides. Inject into abdominal fat, thigh, or upper arm. Rotate sites. standard research dose.
Intramuscular Injection High — with slightly faster onset than SC
Alternative route when deeper delivery or faster absorption is desired. Less commonly used than SC for most research peptides.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Cerebrolysin:
Nootropic Stack
Combines Cerebrolysin with Semax (BDNF/cognition) and Selank (anxiolytic) for balanced cognitive enhancement and stress resilience.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 5ml/vial, 10ml/vial, 20ml/vial |
|---|---|
| BAC Water | N/A — supplied as ready-to-use solution; dilute in saline for IV infusion |
| Storage | Refrigerate at 2-8°C; do not freeze; protect from light |
| Shelf Life | 36 months unopened; use immediately once ampule opened |
Need exact syringe measurements?
Amino Acid Sequence
Complex mixture; individual component peptides are small fragments of porcine brain proteins, each <10 kDa
Side Effects & Safety
- Generally well-tolerated with IV/IM administration
- Mild nausea or dizziness at high doses
- Rare allergic reactions
- Injection site reactions
- Seizure threshold lowering (rare, theoretical)
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Mixture — component half-lives vary; single-dose effects ~24 hours |
|---|---|
| Storage | Store ampoules at room temperature (below 25°C), protected from light. Do not freeze. |
Synergistic Compounds
The following compounds have been studied alongside Cerebrolysin for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.